Updated labeling for psoriasis drug Raptiva approved
US FDA Approves Updated Labeling for Psoriasis Drug Raptiva by Genentech; Safety concerns drove labeling changes. – The U.S. Food and Drug Administration announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab).